Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Editorial opinion

May 19th 2016

Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study

This ‘real-world’ study compares the reduction in microalbuminuria (assessed by urine albumin:creatinine ratio [UACR]) seen when adding a gliptin to background metformin therapy, versus that with a sulphonylurea. The conclusion is that both therapies reduce UACR but the gliptin (in this case, sitagliptin) is more efficacious.

There are several health-warnings that need to be applied to this study. It is small (N=564 patients), patients were followed for a very short period (mean of nine months) and the result was a ‘trend’. Furthermore, elevated UACR is a highly variable marker, which needs to be repeated to be valid (in some studies, four timed urine collections have been analysed); this assessment of computerised records used only one spot-test. Moreover, whilst the diabetes community have been brain-washed into thinking that elevations in UACR mean impending dialysis, it is clear that increased UACR can be a result of multiple pathologies and that end-stage renal disease is a highly unlikely outcome for the vast majority of patients with diabetes. This is probably the reason for it dropping off the QoF agenda, although the implication was that it has now become so embedded in GP psychology that it will continue to be assessed without compensation. I doubt that this will prove to be the case, nor do I think that it should be, given that widespread screening for an elevated UACR has ever been justified.

I would suggest that regarding microalbuminuria, appropriate blood pressure control should be the focus rather than UACR and that for gliptins and SUs, HbA1c reduction, hypoglycaemia and weight are the outcomes that should guide choices….

Professor Steve Bain

Categories: News

Categories:

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskSanofi DiabetesAstraZenecaNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)AmgenAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

News Archive

calendar-iconNews Archive ››

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Recent Book and Product Reviews

  • Oxford Handbook of Emergency Medicine
  • Handbook of Obstetric Medicine
  • Ferri’s Clinical Advisor 2021
  • Oxford Case Histories in Infectious Diseases and Microbiology

Recent Diabetes Updates

  • National Diabetes Audit.
  • Funding bids
  • Publication of Studies During 2016 – Type 2 Diabetes
  • “Attitudes to obesity” findings from the 2015 survey

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


Website by Wired up Wales

Copyright © 2021 Glycosmedia Partnership